Status:

COMPLETED

Probiotic Ingestion and Isoagglutinin Titers

Lead Sponsor:

National Institutes of Health Clinical Center (CC)

Conditions:

Isoagglutinin-Mediated Hemolysis

Probiotic Toxicity

Eligibility:

All Genders

18-70 years

Phase:

PHASE1

Brief Summary

Background: * Probiotics are oral food supplements containing live bacteria that may be beneficial to a person s digestion or general health. Probiotics are available as tablets, powder, or liquid su...

Detailed Description

Probiotics are over-the-counter dietary supplements which contain live bacteria. These bacteria are normally present in the gastrointestinal tract and may provide health benefits when added to a regul...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Subjects must be healthy
  • Subjects must be greater than or equal to 18 and less than or equal to 70 years of age
  • Subjects must have an ABC blood group of A, B or O
  • Laboratory values within established guidelines for participation in clinical studies:
  • AST/ALT less than or equal to 2 times ULN; creatinine less than or equal to ULN; hemoglobin greater than or equal to 12.5 g/dL (males and females)
  • Subjects must be willing to sign consent to participate in the protocol
  • EXCLUSION CRITERIA:
  • ABO blood group of AB
  • Current apheresis platelet donor in the NIH DTM
  • Current or past history of gastrointestinal disease or surgery including: Crohn s disease, ulcerative colitis, celiac disease, irritable bowel syndrome, gastric bypass or banding, esophagectomy, gastrectomy, small bowel resection, colectomy, and any history of gastrointestinal malignancy including pancreatic carcinoma
  • Vaccination within the last 2 months, with the exception of the influenza vaccine
  • A history of high risk behaviors for exposure to HIV, HBV, HCV, HTLV (no intravenous drug use in past 5 years, no male sex with males in last 5 years)
  • Confirmed positive test result for anti-HIV-1/2, anti-HCV, anti-HTLV I/Il, anti-T.pallidum, or H BsAg.
  • History of bleeding or clotting disorders
  • History of hematologic malignancy
  • History of inherited or acquired immune deficiency
  • Diabetes mellitus (type I or II)
  • Women of child-bearing potential
  • I) Subjects currently taking immunosuppressive medications
  • m) Subjects who have taken probiotic supplements within the last 12 months

Exclusion

    Key Trial Info

    Start Date :

    April 28 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 6 2011

    Estimated Enrollment :

    36 Patients enrolled

    Trial Details

    Trial ID

    NCT00891787

    Start Date

    April 28 2009

    End Date

    April 6 2011

    Last Update

    October 6 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892